FILED BY ALKERMES, INC. PURSUANT TO RULE 425
                                            UNDER THE SECURITIES ACT OF 1933 AND
                                            DEEMED FILED PURSUANT TO RULE 14A-12
                                          OF THE SECURITIES EXCHANGE ACT OF 1934

                                   SUBJECT COMPANY: RELIANT PHARMACEUTICALS, LLC

                                                  COMMISSION FILE NO.: 132-02240


The Agreement and Plan of Merger by and among Alkermes, Inc., a Pennsylvania
corporation, Reliant Pharmaceuticals, LLC, a Delaware limited liability company,
New Alkermes, Inc., a Pennsylvania corporation and a wholly-owned subsidiary of
Alkermes, Adams Acquisition Sub, Inc., a Pennsylvania corporation and a
wholly-owned subsidiary of Alkermes and Revere Acquisition Sub, LLC, a Delaware
limited liability company and a wholly-owned subsidiary of Alkermes was filed by
Alkermes, Inc. under cover of Form 8-K today and is incorporated by reference
into this filing.

IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC

In connection with the proposed Alkermes/Reliant merger, a joint proxy
statement/prospectus will be filed with the Securities and Exchange Commission
(the "SEC"). INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE JOINT PROXY
STATEMENT/PROSPECTUS REGARDING THE PROPOSED MERGER WHEN IT BECOMES AVAILABLE,
BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION. Investors may obtain a free copy
of the joint proxy statement/prospectus (when it is available) and other
documents filed by Alkermes with the SEC at the SEC's website at www.sec.gov.
The joint proxy statement/prospectus (when it is available) and these other
documents may also be obtained for free from Alkermes by calling Alkermes at
(617) 494-0171 and on the Alkermes website at www.alkermes.com.

Alkermes and its directors, executive officers and certain other members of
management and employees may be soliciting proxies from its shareholders in
favor of the proposed merger. Information regarding the persons who may, under
the rules of the SEC, be considered to be participants in the solicitation of
Alkermes shareholders in connection with the proposed Alkermes/Reliant merger is
set forth in Alkermes' proxy statement for its 2001 annual meeting, dated June
22, 2001 and filed with the SEC on June 28, 2001. Additional information will be
set forth in the joint proxy statement/prospectus when it is filed with the SEC.